2nd annual Pharma and Biotech IP Summit

Programme

  •  
  •  
    8:00 am  -  9:00 am
    Registration and morning coffee
    9:00 am  -  9:15 am
    Chair’s welcome
    9:15 am  -  10:30 am
    Building IP business strategies in the new political and legislative landscape

    Intellectual property plays a key role in the pharma and biotech sectors, not just as an enabler of competition and profit, but also to assist in establishing a strong and effective public health infrastructure. As the political and legislative landscape changes, IP strategies must continue to adapt and grow.

    • Improving patent quality and protection
    • How patentable should patents be – encouraging competition versus stifling innovation
    • Creating opportunities and reviewing risks in the patent market
    Moderator:
    10:30 am  -  11:10 am
    Networking break
    11:10 am  -  12:00 pm
    Patentability in Europe, the United States and China

    Distinct approaches to patent eligibility are emerging in the United States, Europe and China. If they are to protect their interests, it is vital that life sciences companies understand these differences.

    • Recent court decisions and their impact on patentability across different jurisdictions
    • Working with patent office examiners to get the protection you need
    • Emerging alternatives to patent protection – using trade secrets
    Moderator:
    Panellists:
    12:00 pm  -  12:50 pm
    Patent litigation in Europe

    Europe presents unique challenges when it comes to litigating patents; doubts around the Unified Patent Court (UPC) agreement and Brexit only serve to complicate things further. This session reviews the key areas of concern and provide comparison points with the US landscape.

    • Where now for the UPC?
    • Will Brexit change anything for litigation?
    • Planning a European/US strategy
    Moderator:
    12:50 pm  -  2:00 pm
    Lunch and networking break
    2:00 pm  -  2:30 pm
    Litigation of biosimilars

    As Europe’s biosimilar market continues to grow and new classes are approved, the United States is taking a different ‘patent dance’ path. This session assesses the impact of recent developments on both sides of the Atlantic.

    • Assessing recent disputes and their outcomes
    • The scope of jurisdiction
    • The impact of increased competition
    2:30 pm  -  3:00 pm
    The view from the United States

    An overview of key US litigation developments, including a Hatch-Waxman update; an assessment of the impact of the inter partes review regime on life sciences industries; and how to plan a protection strategy for the United States.

    Speaker:
    3:00 pm  -  3:30 pm
    Networking break
    3:30 pm  -  4:10 pm
    Second medical use patents

    With significant research now taking place in relation to existing medicines and compounds, looking at additional uses, incentivisation and reimbursement is a key IP issue. Although recent litigation has helped innovators to protect their rights to some extent, many questions remain.

    • Assessing how recent litigation has affected the landscape
    • Harmonisation of reimbursement and pricing
    • Is the current regime stifling innovation?
    • Key issues in cross-labelling
    Moderator:
    Panellists:
    4:10 pm  -  5:00 pm
    Supplementary Protection Certificates - patent extentions in Europe

    There have been a flurry of supplementary protection certificate referrals to the European Court of Justice (ECJ) coinciding with the European Commission’s incentives review. This session looks at potential changes and their impact.

    • Understanding the recent ECJ referrals and their consequences
    • Assessing the European Commission’s review and its likely outcomes
    • How IP strategies will need to adapt
    Moderator:
    Panellists:
    5:00 pm  -  5:00 pm
    Close of day
Top